Andrew Cheng, Akero Therapeutics CEO
June 5, 2023 11:19 AM EDT
R&D

Akero’s NASH can­di­date re­duces liv­er fat in pa­tients tak­ing a GLP-1

Paul Schloesser

Associate Editor

Akero Ther­a­peu­tics said its NASH drug re­duced liv­er fat in pa­tients who were al­so tak­ing a GLP-1 ag­o­nist.

The NASH-fo­cused biotech on Mon­day

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times